Concomitant diseases in COVID-19 and their impact on the risks of adverse outcomes

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To analyze COVID-19 comorbidities and their impact on disease course and the risk for unfavorable outcomes.

Methods. This study examined a group of 110 patients aged 32 to 97 who were admitted to the intensive care unit of the Pskov Regional Infectious Diseases Hospital in the period from October 7, 2020 to March 23, 2021. The mean age of patients was 65 years, 51% (56 people) were male. The study recorded age, comorbidities on a binary scale (yes — no), course of the disease, the degree of lung injury, hospital length of stay, treatment outcome. The impact of comorbidities on the disease severity and outcomes was assessed by using logistic regression analysis.

Results. It was shown that a regional sample of patients showed an increased hospital mortality rate compared with the data of the ACTIV registry (33.5 versus 7.6%). Chronic respiratory diseases in patients with COVID-19 regional cohorts affected the fatal outcome 2.7 times less than those registered in the Russian register. The presence of endocrine and thrombotic circulatory system diseases was generally close to the register. Concomitant cardiovascular diseases in patients of the regional cohort affected the mortality of COVID-19 outcomes two times less (in patients of the region, the risk of mortality increased by 2.066 times) than in the registry. The reliability of the conclusions is confirmed by testing statistical hypotheses and reliability coefficients below 5%.

Conclusion. The study shows the statistically significant effect of comorbidities on the COVID-19 outcomes; the specificity of the results related to the sampling characteristics and the regional component.

Full Text

Restricted Access

About the authors

N V Ivanova

Pskov State University

Author for correspondence.
Email: zdravuniver@inbox.ru
Russian Federation, Pskov, Russia

V S Belov

Pskov State University

Email: zdravuniver@inbox.ru
Russian Federation, Pskov, Russia

A I Samarkin

Pskov State University

Email: zdravuniver@inbox.ru
Russian Federation, Pskov, Russia

Z N Tretyakevich

Pskov State University

Email: zdravuniver@inbox.ru
Russian Federation, Pskov, Russia

V M Mikushev

Saint-Petersburg State University

Email: zdravuniver@inbox.ru
Russian Federation, Saint-Petersburg, Russia

Yu V Bruttan

Pskov State University

Email: zdravuniver@inbox.ru
Russian Federation, Pskov, Russia

References

  1. Brugliera L., Spina A., Castellazzi P., Cimino P., Tettamanti A., Houdayer E., Arcuri P., Alemanno F., Mortini P., Iannaccone S. Rehabilitation of COVID-19 patients. J. Rehabil. Med. 2020; 52 (4): jrm00046. doi: 10.2340/16501977-2678.
  2. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report — 48. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4 (access date: 27.08.2021).
  3. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061–1069. doi: 10.1001/jama.2020.1585.
  4. Baumann T., Delgado J., Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. Leukemia. 2020; 34: 1–3.
  5. Arutyu-nov G.P., Tarlovskaya E.I., Arutyunov A.G., Belenkov Y.N., Konradi A.O., Lopatin Y.M., Rebrov A.P., Tereshchenko S.N., Chesnikova A.I., Hayrapetyan H.G., Babin A.P., Bakulin I.G., Bakulina N.V., Balykova L.A., Blagonra¬vova A.S., Boldina M.V., Vaisberg A.R., Galya¬vich A.S., Gomonova V.V., Grigorie¬va N.U., Gubareva I.V., Demko I.V., Evzerikhina A.V., Zharkov A.V., Kamilova U.K., Kim Z.F., Kuznetsova T.Yu., Lareva N.V., Makarova E.V., Malchikova S.V., Nedogoda S.V., Petrova M.M., Pochinka I.G., Protasov K.V., Protsenko D.N., Ruzanov D.Yu., Sayganov S.A., Sarybaev A.Sh., Selezneva N.M., Sugraliev A.B., Fomin I.V., Khlynova O.V., Chizhova O.Yu., Shaposhnik I.I., Sсhukarev D.A., Abdrahmanova A.K., Avetisian S.A., Avoyan H.G., Aza¬rian K.K., Aimakhanova G.T., Ayipova D.A., Akunov A.Ch., Alieva M.K., Aparkina A.V., Aruslanova O.R., Ashina E.Yu., Badina O.Y., Barisheva O.Yu., Batchayeva A.S., Bitieva A.M., Bikhteyev I.U., Borodulina N.A., Bragin M.V., Budu A.M., Burygina L.A., Bykova G.A., Varlamova D.D., Vezikova N.N., Verbitskaya E.A., Vilkova O.E., Vinnikova E.A., Vustina V.V., Gаlova E.A., Genkel V.V., Gorshenina E.I., Gostishev R.V., Grigorieva E.V., Gubareva E.Yu., Dabylova G.M., Demchenko A.I., Dolgikh O.Yu., Duva¬nov I.A., Duyshobayev M.Y., Evdokimov D.S., Egorova K.E., Ermilova A.N., Zheldybayeva A.E., Zarechnova N.V., Ivanova S.Yu., Ivan¬chenko E.Yu., Ilina M.V., Kazakovtseva M.V., Kazymova E.V., Kalinina Yu.S., Kamardina N.A., Karachenova A.M., Karetnikov I.A., Karoli N.A., Karpov O.V., Karsiev M.Kh., Кaskaeva D.S., Kasymova K.F., Kerimbekova Zh.B., Kerimova A.Sh., Kim E.S., Kiseleva N.V., Klimenko D.A., Klimova A.V., Kovalishena O.V., Kolmakova E.V., Kolchinskaya T.P., Kolyadich M.I., Kondriakova O.V., Konoval M.P., Konstantinov D.Yu., Konstantinova E.A., Kordukova V.A., Koroleva E.V., Kraposhina A.Yu., Kriukova T.V., Kuznetsova A.S., Kuzmina T.Y., Kuzmichev K.V., Kulchoroeva Ch.K., Kuprina T.V., Kouranova I.M., Kurenkova L.V., Kurchugina N.Yu., Kushubakova N.A., Levankova V.I., Levin M.E., Lyubavina N.A., Magdeyeva N.A., Mazalov K.V., Majseenko V.I., Makarova A.S., Maripov A.M., Marusina A.A., Melnikov E.S., Moiseenko N.B., Muradova F.N., Muradyan R.G., Musaelian Sh.N., Nikitina N.M., Ogurlieva B.B., Odegova A.A., Omarova Yu.M., Omurzakova N.A., Ospanova Sh.O., Pahomova E.V., Petrov L.D., Plastinina S.S., Pogrebetskaya V.A., Polyakov D.S., Ponomarenko E.V., Popova L.L., Prokofeva N.A., Pudova I.A., Rakov N.A., Rakhimov A.N., Rozanova N.A., Serikbolkyzy S., Simo¬nov A.A., Skach¬kova V.V., Smirnova L.A., Soloveva D.V., Soloveva I.A., Sokh¬ova F.M., Subbotin A.K., Sukhomlinova I.M., Sushilova A.G., Tagayeva D.R., Titojkina Yu.V., Tikhonova E.P., Tokmin D.S., Torgunakova M.S., Trenogina K.V., Trostiane¬tckaia N.A., Trofimov D.A., Tulichev A.A., Tupitsin D.I., Tursunova A.T., Ulanova N.D., Fatenkov O.V., Fedo¬rishina O.V., Fil T.S., Fomina I.Yu., Fominova I.S., Frolova I.A., Tsvinger S.M., Tsoma V.V., Cholponbaeva M.B., Chudinovskikh T.I., Shakhgildyan L.D., Shevchenko O.A., Sheshina T.V., Shishkina E.A., Shish-kov K.Yu., Sherbakov S.Y., Yausheva E.A. Internatio¬nal register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Russian Journal of Cardio¬logy. 2021; 26 (4): 4470. (In Russ.) doi: 10.15829/1560-4071-2021-4470.
  6. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clini¬cal predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. ¬Intensive Care Med. 2020; 46 (5): 846–848. doi: 10.1007/s00134-020-05991-x.
  7. Tkacheva O.N., Kotovskaya Yu.V., Aleksanyan L.A., Milto A.S., Naumov A.V., Strazhesko I.D., Vorobyeva N.M., Dudinskaya E.N., Malaya I.P., Krylov K.Yu., Tyukhmenev E.A., Rozanov A.V., Ostapenko V.S., Manevich T.M., Shchedrina A.Yu., Semenov F.A., Mkhitaryan E.A., Khovasova N.O., Yerulanova E.A., Kotovskaya N.V., Sharashkina N.V. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Kardiovaskulyarnaya terapiya i profilaktika. 2020; 19 (3): 2601. (In Russ.) doi: 10.15829/1728-8800-2020-2601.
  8. Chinese Center for Control and Prevention. http://www.chinacdc.cn/en/COVID19/ (access date: 27.08.2021).
  9. Vital surveillances: The epidemiological characte¬ristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China. 2020. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51/ (access date: 28.08.2021).
  10. Remuzzi A., Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020; 395 (10231): 1225–1228. doi: 10.1016/S0140-6736(20)30627-9.
  11. Porcheddu R., Serra C., Kelvin D., Kelvin N., Rubino S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J. Infect. Dev. Ctries. 2020; 14 (2): 125–128. doi: 10.3855/jidc.12600.
  12. Bubnova M.G., Shlyakhto E.V., Aronov D.M., Belevsky A.S., Gerasimenko M.Yu., Glezer M.G., Gordeev M.N., Drapkina O.M., Ivanova G.E., Ioseliani D.G., Karamnova N.S., Kosmacheva E.D., Kuleshov A.V., Kukshina A.A., Lyadov K.V., Lyamina N.P., Makarova M.R., Meshcheryakova N.N., Nikityuk D.B., Pasechnik I.N., Persiyanova-Dubrova A.L., Pogonchenkova I.V., Svet A.V., Starodubova A.V., Tutelyan V.A. Coronavirus disease 2019: features of comprehensive cardiac and pulmonary rehabi-litation. Russian Journal of Cardiology. 2021; 26 (5): 4487. (In Russ.) doi: 10.15829/1560-4071-2021-4487.
  13. Drapkina O.M., Karpov O.E., Lukyanov M.M., Martsevich S.Yu., Pulin A.A., Kutishenko N.P., Akimkin V.G., Andreenko E.Yu., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Zagrebelny A.V., Lerman O.V., Makoveeva A.N., Okshina E.Yu., Kudryashov E.V., Klyashtorny V.G., Smirnov A.A., Fomina V.S. Prospective inhospital registry of patients with suspected or documented COVID-19 infection and community-acquired pneumonia (TARGET-VIP): characteristics of patients and assessment of in-hospital outcomes. Kardiovaskulyarnaya terapiya i profilaktika. 2020; 19 (6): 2727. (In Russ.) doi: 10.15829/1728-8800-2020-2727.
  14. Pranata R., Huang I., Lim M.A., Wahjoepramono E.J., July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J. Stroke Cerebrovasc. Dis. 2020; 29 (8): 104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949.
  15. Tanashyan M.M., Kuznetsova P.I., Raskurazhev A.A. Neurological aspects of COVID-19. Annaly klinicheskoy i eksperimental'noy nevrologii. 2020; 14 (2): 62–69. (In Russ.) doi: 10.25692/ACEN.2020.2.8.
  16. Lya¬lyukova E.A., Dolgalev I.V., Chernysheva E.N., Druk I.V., Konovalova G.M., Lyalуukov A.V. COVID-19 and liver dysfunction: current ideas and new therapeutic strategies. Lechaschi Vrach. 2021; (2): 20–25. (In Russ.) doi: 10.26295/OS.2021.16.99.004.
  17. Kuklina G.M., Makar'iants N.N. Description of COVID-19 infection course in a patient with multiple comorbidity: hairy cell leukemia, chronic generalized sarcoidosis and deep vein thrombosis in the lower extremities. Case report. Consilium Medicum. 2021; 23 (3): 292–295. (In Russ.) doi: 10.26442/20751753.2021.3.200815.
  18. Abdurakhma¬nov I.U., Umurzakov Sh.E., Zhamilova G.K., Satarova A.A., Aida¬rov Z.A. COVID-19 and comorbid pathology (literature review). The Scientific Heritage. 2021; (68): 56–64. (In Russ.)
  19. National Institute for Health and Care Excellence, Royal College of General Practitioners, Healthcare Improvement Scotland SIGN. COVID-19 rapid guideline: managing the longterm effects of COVID-19. London: National Institute for Health and Care Excellence. 2020. https://www.nice.org.uk/guidance/ng188 (access date: 18.12.2020).
  20. Glybochko P.V., Fomin V.V., Avdeev S.N., Moiseev S.V., Yavorovsky A.G., Brovko M.Yu., Umbetova K.T., Aliev V.A., Bulanova E.L., Bondarenko I.B., Volkova O.S., Gainitdinova V.V., Gneusheva T.Yu., Dubrovin K.V., Kapustina V.A., Kraeva V.V., Merzhoeva Z.M., Nuralieva G.S., Nail P.V., Panasyuk V.V., Politov M.E., Popov A.M., Po¬pova E.N., Raspopina N.A., Royuk V.V., Sorokin Yu.D., Trushenko N.V., Khalikova E.Yu., Tsareva N.A., Chikina S.Yu., Chichkova N.V., Akulkina L.A., Bulanov N.M., Ermolova L.A., Zykova A.S., Kitbalyan A.A., Moiseev A.S., Potapov P.P., Tao E.A., Sholomova V.I., Shchepalina A.A., Yakovleva A.A. Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia. Klini¬cheskaya farmakologiya i terapiya. 2020; 29 (2): 21–29. (In Russ.) doi: 10.32756/0869-5490-2020-2-21-29.
  21. Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46 (4): 586–590. doi: 10.1007/s00134-020-05985-9.
  22. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579 (7798): 270–273. doi: 10.1038/s41586-020-2012-7.
  23. Mitkovskaya N., Grigorenko E., Ruzanov D., Statkeych T. COVID-19 coronavirus infection and comorbidity. Nauka i innovatsii. 2020; (7): 50–60. (In Russ.) doi: 10.29235/1818-9857-2020-7-50-60.
  24. Ling L., Lianfeng L., Wei C., Taisheng L. Hypothesis for potential pathogenesis of SARS-CoV-2 infection — a review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect. 2020; 9 (1): 727–732. doi: 10.1080/22221751.2020.1746199.
  25. Siddiqu H.K., Mehra M.R. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J. Heart Lung Transplant. 2020; 39 (5): 405–407. doi: 10.1016/j.healun.2020.03.012.
  26. Samsonova M.V., Chernyaev A.L., Omarova Zh.R., Pershina E.A., Mishnev O.D., Zayratyants O.V., Mikhaleva L.M., Kalinin D.V., Varyasin V.V., Tishkevich O.A., Vinogradov S.A., Mikhaylichenko K.Yu., Chernyak A.V. Features of pathological anatomy of lungs at COVID-19. Pul’monologiya. 2020; 30 (5): 519–532. (In Russ.) doi: 10.18093/0869-0189-2020-30-5-519-532.
  27. Lippi G., Henry B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir. Med. 2020; 167: 105941. doi: 10.1016/j.rmed.2020.105941.
  28. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., Zhang Y., Song J., Wang S., Chao Y., Yang Z., Xu J., Zhou X., Chen D., Xiong W., Xu L., Zhou F., Jiang J., Bai C., Zheng J., Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020; 180 (7): 934–943. doi: 10.1001/jamainternmed.2020.0994.
  29. Parohan M., Yaghoubi S., Seraji A., Javanbakht M.H., Sarraf P., Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020; 23 (5): 1416–1424. doi: 10.1080/13685538.2020.1774748.
  30. Bunova S.S., Okhotnikova P.I., Skirdenko Yu.P., Nikolaev N.A., Osipova O.A., Zhernakova N.I. COVID-19 andcardiovascular comorbidity: novel approaches to reduce mortality. Kardiovaskulyarnaya terapiya i profilaktika. 2021; 20 (4): 2953. (In Russ.) doi: 10.15829/1728-8800-2021-2953.
  31. Chung M., Zidar D., Bristow M., Cameron S., Chan T., Harding C.V. 3rd., Kwon D., Singh T., Tilton J., Tsai E., Tucker N., Barnard J., Loscalzo J. COVID-19 and cardiovascular disease. Circ. Res. 2021; 128 (8): 1214–1236. doi: 10.1161/CIRCRESAHA.121.317997.
  32. Bubnova M.G., Aronov D.M. COVID-19 and сardiovascular diseases: from epidemiology to rehabilitation. Pul’monologiya. 2020; 30 (5): 688–699. (In Russ.) doi: 10.18093/0869-0189-2020-30-5-688-699.
  33. Siripanthong B., Nazarian S., Muser D., Deo R., Santangeli P., Khanji M.Y., Cooper L.T.Jr., Chahal C.A.A. Recognizing COVID-19 — related myocarditis: The pos¬sible pathophysiology and proposed guideline for diagnosis and management. Hear. Rhythm. 2020; 17 (9): 1463–1471. doi: 10.1016/j.hrthm.2020.05.001.
  34. Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5 (7): 811–818. doi: 10.1001/jamacardio.2020.1017.
  35. Hessami A., Shamshirian A., Heydari K., Pourali F., Alizadeh-Navaei R., Moosazadeh M., Abrotan S., Shojaie L., Sedighi S., Shamshirian D., Rezaei N. Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. Am. J. Emerg. Med. 2021; 46: 382–391. doi: 10.1016/j.ajem.2020.10.022.
  36. Petrikov S.S., Ivannikov A.A., Vasilchenko M.K., Esaulenko A.N., Alidzhanova Kh.G. COVID-19 and cardiovascular system: Pathophysiology, pathomorphology, complications, long-term prognosis. Zhurnal im. N.V. Sklifosovskogo. Neotlozhnaya medicinskaya pomoshch'. 2021; 10 (1): 14–26. (In Russ.) doi: 10.23934/2223-9022-2021-10-1-14-26.
  37. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., Huisman M.V., Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020; 191: 145–147. doi: 10.1016/j.thromres.2020.04.013.
  38. Poissy J., Goutay J., Caplan M., Parmentier E., Duburcq T., Lassalle F., Jeanpierre E., Rauch A., Labreuche J., Susen S. Lille ICU Haemostasis COVID-19 group. Pulmonary Embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020; 142: 184–186. doi: 10.1161/CIRCULATIONAHA.120.047430.
  39. Inciardi R.M., Adamo M., Lupi L., Cani D.S., Di Pasquale M., Tomasoni D., Italia L., Zaccone G., Tedino C., Fabbricatore D., Curnis A., Faggiano P., Gorga E., Lombardi C.M., Milesi G., Vizzardi E., Volpini M., Nodari S., Specchia C., Maroldi R., Bezzi M., Metra M. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur. Heart J. 2020; 41: 1821–1829. doi: 10.1093/eurheartj/ehaa388.
  40. Andreeva A.V., Markova T.N., Antsiferov M.B. Management of patients with diabetes mellitus and COVID-19. Doctor.Ru. 2021; 20 (2): 11–20. (In Russ.) doi: 10.31550/1727-2378-2021-20-2-11-20.
  41. Mokrysheva N.G., Galstyan G.R., Kirzhakov M.A., Eremkina A.K., Pigarova E.A., Melnichenko G.A. COVID-19 Pandemic and endocrinopathies. Problemy Endocrinologii. 2020; 66 (1): 7–13 (In Russ.) doi: 10.14341/probl12376.
  42. Finer N., Garnett S.P., Bruun J.M. COVID-19 and obesity. Clin. Obes. 2020; 10 (3); 12365. doi: 10.1111/cob.12365.
  43. Imanov B.Zh., Murkamilov I.T., Sabirov I.S., Sarybaev A.Sh. Effect of renal dysfunction on the cardiac-vascular system. The possibilities of early dia¬gnosis of the renal dysfunction. The Russian Archives of Internal Medicine. 2018; 8 (4): 260–265. (In Russ.) doi: 10.20514/2226-6704-2018-8-4-260-265.
  44. Vykhrystsenka L.R., Schastlivenko A.I., Bondareva L.I., Sidarenko A.V., Muzyka O.G. Kidney damage in COVID-19 infection. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta. 2021; 20 (1): 7–23. (In Russ.) doi: 10.22263/2312-4156.2021.1.7.
  45. Su H., Yang M., Wan C., Yi L.X., Tang F., Zhu H.Y., Yi F., Yang H.C., Fogo A.B., Nie X., Zhang C. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020; 98 (1): 219–227. doi: 10.1016/j.kint.2020.04.003.
  46. Ali N., Hossain K. Liver injury in severe COVID-19 infection: current insights and challenges. Expert. Rev. Gastroenterol. Hepatol. 2020; 14 (10): 879–884. doi: 10.1080/17474124.2020.1794812.
  47. Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., Li Z., Zhou G., Gou J., Qu J., Sun Y., Liu Y., He Q., Chen J., Liu L., Xu L. COVID-19: Abnormal liver function tests. J. Hepatol. PMC. PubMed. 2020; 73: 566–574. doi: 10.1016/j.jhep.2020.04.006.
  48. Olry A., Meunier L., Delire B., Larrey D., Horsmans Y., Le Louet H. Drug induced liver injury and COVID-19 infection: The rules remain the same drug safety. 2020; 43: 615–617. doi: 10.1007/s40264-020-00954-z.
  49. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J.; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395: 1033–1034. doi: 10.1016/s0140-6736(20)30628-0.
  50. Feng G., Zheng K.I., Yan Q.Q., Rios R.S., Targher G., Byrne C.D., Poucke S.V., Liu W.Y., Zheng M.H. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J. Clin. Transl. Hepatol. 2020; 8 (1): 18–24. doi: 10.14218/JCTH.2020.00018.
  51. Singh S., Khan A. Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study. Gastroenterology. 2020; 159 (2): 768–771. doi: 10.1053/j.gastro.2020.04.064.
  52. Petrov V.I., Ponomareva A.V., Ivakhnenko I.V., Razvalyaeva O.V., Meshrqi B.A., Statsenko V.I. Etiopathogenetic aspects of liver injury in patients with COVID-19. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta. 2020; (4): 9–15. (In Russ.) doi: 10.19163/1994-9480-2020-4(76)-9-15.
  53. Novikova L.B., Akopian A.P., Sharapova K.M., Latypova R.F. Neurological and mental disorders associated with COVID-19. Arterial Hypertension. 2020; 26 (3): 317–326. (In Russ.) doi: 10.18705/1607-419X-2020-26-3-317-326.
  54. Shepeleva I.I., Chernysheva A.A., Kiryanova E.M., Salnikova L.I., Gurina O.I. The nervous system damages and psychological and psychiatric complications on the covid-19 pandemic. Sotsial'naya i klinicheskaya psi¬khiatri. 2020; 30 (4): 76–82. (In Russ.)
  55. Li Y.C., Bai W.Z., Hashikawa T. The neuroinvasive potential of SARSCoV-2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. 2020; 92 (7): 703–704. doi: 10.1002/jmv.25728.
  56. Belopasov V.V., Yachou Y., Samoilova E.M., Baklaushev V.P. The Nervous System Damage in COVID-19. Klinicheskaya praktika. 2020; 11 (2): 60–80. (In Russ.) doi: 10.17816/clinpract34851.
  57. Trejo-Gabriel-Galán J.M. Stroke as a complication and prognostic factor of COVID-19. Neurologia. 2020; 35 (5): 318–322. doi: 10.1016/j.nrl.2020.04.015.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

© 2021 Eco-Vector




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies